Arshad M. Khanani, MD, MA, and Carl D. Regillo, MD, discuss the current state of neovascular age-related macular degeneration treatments, the benefits of sustained-delivery of anti-VEGF agents, and additional treatments in development. This webinar also features surgical videos highlighting key techniques.
This continuing medical education activity is supported through educational grant from Genentech, a member of the Roche Group.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Recommended internet speed 5Mbps+
Arshad M. Khanani, MD, MA
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno School of Medicine
Carl D. Regillo, MD
Professor of Ophthalmology
Thomas Jefferson University
Director, The Retina Service of Wills Eye Hospital
Partner, Mid Atlantic Retina
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.
The following faculty/staff members have the following financial relationships with commercial interests:
Arshad M. Khanani, MD, MA; and or spouse; has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerpio, Allegro, Allergan, Graybug, Genentech, Gyroscope, Kodiak, Notal Vision, Novartis, Opthea, Orbit BioMedical, Oxurion, Polyphotonix, Recens Medical, and Regenexbio. Grant/Research Support: Advernum, Aerpio, Allergan, Gemini, Genentech, Graybug, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, Recens Medical, and Regenxbio. Speaker’s Bureau: Allergan, Genentech, and Novartis.
Carl Regillo, MD, and/or spouse, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Advernum, Allergan, Chengdu Kanghing, Eyepoint, Genentech, Graybug Vision, IVERIC bio, Kodiak Sciences, Merck, Novartis, and Opthea. Grant/Research Support: Advernum, Allergan, Genentech, Gemini Therapeutics, Gyroscope Therapeutics, IVERIC bio, Kodiak Sciences, Novartis, Opthea, Regeneron Pharmaceuticals, and Regenxbio.
The staff and planners at Evolve Medical Education have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.